288 related articles for article (PubMed ID: 25996664)
1. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract][Full Text] [Related]
2. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract][Full Text] [Related]
3. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.
Liu X; Chong Y; Tu Y; Liu N; Yue C; Qi Z; Liu H; Yao Y; Liu H; Gao S; Niu M; Yu R
J Hematol Oncol; 2016 Oct; 9(1):108. PubMed ID: 27733172
[TBL] [Abstract][Full Text] [Related]
4. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
[TBL] [Abstract][Full Text] [Related]
5. CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.
Liu X; Chong Y; Liu H; Han Y; Niu M
Korean J Physiol Pharmacol; 2016 Mar; 20(2):161-8. PubMed ID: 26937212
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
[TBL] [Abstract][Full Text] [Related]
7. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms.
Meissner T; Krause E; Vinkemeier U
FEBS Lett; 2004 Oct; 576(1-2):27-30. PubMed ID: 15474004
[TBL] [Abstract][Full Text] [Related]
8. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway.
Saito N; Sakakibara K; Sato T; Friedman JM; Kufe DW; VonHoff DD; Kawabe T
Mol Cancer Ther; 2014 Dec; 13(12):3013-23. PubMed ID: 25253782
[TBL] [Abstract][Full Text] [Related]
9. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
[TBL] [Abstract][Full Text] [Related]
10. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
Lei Y; An Q; Shen XF; Sui M; Li C; Jia D; Luo Y; Sun Q
J Med Chem; 2021 May; 64(10):6596-6607. PubMed ID: 33974430
[TBL] [Abstract][Full Text] [Related]
11. Leptomycin B alters the subcellular distribution of CRM1 (Exportin 1).
Rahmani K; Dean DA
Biochem Biophys Res Commun; 2017 Jun; 488(2):253-258. PubMed ID: 28412356
[TBL] [Abstract][Full Text] [Related]
12. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis.
Connor MK; Kotchetkov R; Cariou S; Resch A; Lupetti R; Beniston RG; Melchior F; Hengst L; Slingerland JM
Mol Biol Cell; 2003 Jan; 14(1):201-13. PubMed ID: 12529437
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
[TBL] [Abstract][Full Text] [Related]
14. Nuclear export of proteins and drug resistance in cancer.
Turner JG; Dawson J; Sullivan DM
Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways.
Pathria G; Wagner C; Wagner SN
J Invest Dermatol; 2012 Dec; 132(12):2780-90. PubMed ID: 22832492
[TBL] [Abstract][Full Text] [Related]
17. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1.
Sun Q; Carrasco YP; Hu Y; Guo X; Mirzaei H; Macmillan J; Chook YM
Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1303-8. PubMed ID: 23297231
[TBL] [Abstract][Full Text] [Related]
18. CRM1 Promotes Capsid Disassembly and Nuclear Envelope Translocation of Adenovirus Independently of Its Export Function.
Lagadec F; Carlon-Andres I; Ragues J; Port S; Wodrich H; Kehlenbach RH
J Virol; 2022 Feb; 96(3):e0127321. PubMed ID: 34757845
[TBL] [Abstract][Full Text] [Related]
19. CRM1-dependent, but not ARE-mediated, nuclear export of IFN-alpha1 mRNA.
Kimura T; Hashimoto I; Nagase T; Fujisawa J
J Cell Sci; 2004 May; 117(Pt 11):2259-70. PubMed ID: 15126627
[TBL] [Abstract][Full Text] [Related]
20. Crm1 is a mitotic effector of Ran-GTP in somatic cells.
Arnaoutov A; Azuma Y; Ribbeck K; Joseph J; Boyarchuk Y; Karpova T; McNally J; Dasso M
Nat Cell Biol; 2005 Jun; 7(6):626-32. PubMed ID: 15908946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
